Comparative Pharmacology
Head-to-head clinical analysis: DEXRAZOXANE HYDROCHLORIDE versus ZINECARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXRAZOXANE HYDROCHLORIDE versus ZINECARD.
DEXRAZOXANE HYDROCHLORIDE vs ZINECARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexrazoxane is a cardioprotective agent that acts as a topoisomerase II inhibitor and iron chelator. It reduces the cardiotoxicity of anthracyclines by binding to iron and preventing the formation of anthracycline-iron complexes that generate reactive oxygen species. It also inhibits topoisomerase II, which may contribute to its cardioprotective effects.
Dextrazoxane is a cardioprotective agent. It is a derivative of EDTA that chelates iron, reducing iron-dependent free radical formation that causes anthracycline-induced cardiotoxicity. It also inhibits topoisomerase II beta, which may contribute to its cardioprotective effects.
500 mg/m² IV over 15-30 minutes, starting within 30 minutes before doxorubicin, at a 10:1 ratio (dexrazoxane:doxorubicin).
500-1000 mg/m² intravenously once daily for 3 consecutive days, beginning prior to doxorubicin administration.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours; clinical context: supports every-3-week dosing schedule
Terminal elimination half-life: 2.5 to 3.0 hours in patients with normal renal function; clinically, elimination may be prolonged in renal impairment.
Primarily renal (40-60% unchanged drug); minor biliary/fecal (<10%)
Renal: approximately 50-60% as unchanged drug; fecal: negligible; biliary: minimal.
Category C
Category C
Cardioprotectant
Cardioprotectant